CAR-T therapy in acute and chronic leukemias: where are we now and where are we heading?
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, shares some insights into clinical indications for CAR-T therapy in acute and chronic leukemias, highlighting recent updates and challenges in this space. Prof. Gribben first discusses the role of CAR-T therapy in acute lymphoblastic leukemia (ALL), drawing focus on the two approved products in this malignancy: tisagenlecleucel (tisa-cel) and brexucabtagene autoleucel (brexu-cel). Prof. Gribben then goes on to explain mechanisms of resistance to CAR-T therapy in ALL and ongoing academic research in this space. Following this, Prof. Gribben discusses updates and challenges with the use of CAR-T therapy in T-cell malignancies and acute myeloid leukemia (AML), and concludes by highlighting challenges with developing efficacious CAR-T products for patients with chronic lymphocytic leukemia (CLL), which may be overcome by combining CAR-T cells with Bruton's tyrosine kinase (BTK) inhibitors. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
No comments found